Evolent Health's oncology experts reported a significant achievement in reducing the use of low-value oncology regimens by over 20%. This reduction occurred from February through May 2024, compared to the same four-month period in 2023, following a multifaceted provider education and engagement campaign with a national payer partner.
The program identified regimens associated with lower survival, more severe side effects, or extremely high costs without additional clinical benefits across 10 common cancer types. Provider requests for these low-value regimens specifically dropped by 15.5%, demonstrating a shift in ordering habits.
This initiative showcases the power of Evolent's provider engagement model, leveraging technology, performance reporting, and incentive structures to drive change. The company's Chief Medical Officer, Dr. Von Nguyen, emphasized that increasing provider awareness and providing tools are critical to sustaining improvements in care quality and affordability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.